Metrochem API Private Limited Metrochem API Private Limited

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Eris Pharmaceuticals","sponsor":"Biocon Biologics","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"India's Biocon to sell branded formulations business to Eris Lifesciences for $150 mln","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Eris Pharmaceuticals

    Menu

    Eris Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Eris Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              India's Biocon to sell branded formulations business to Eris Lifesciences for $150 mln

              Details:

              The collaboration aims to support the Biocon for the commercialization of ACTIBLOK IPR 25 (metoprolol succinate). It is an approved product indicated for the treatment of hypertension and angina pectoris.

              Lead Product(s): Metoprolol Succinate

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACTIBLOK IPR 25

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Biocon Biologics

              Deal Size: $150.0 million Upfront Cash: Undisclosed

              Deal Type: Collaboration March 13, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Veranova: A CDMO that manages complexity with confidence.
              Axplora- The partner of choice for complex APIs.
              Post Enquiry
              POST ENQUIRY